Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
Replimune Inc.
BicycleTx Limited
Bolt Biotherapeutics, Inc.
Olivia Newton-John Cancer Research Institute
University of California, San Diego
Fondazione per la Medicina Personalizzata
Jules Bordet Institute